177 related articles for article (PubMed ID: 21106656)
1. Midregional proatrial natriuretic peptide predicts survival in exacerbations of COPD.
Bernasconi M; Tamm M; Bingisser R; Miedinger D; Leuppi J; Müller B; Christ-Crain M; Stolz D
Chest; 2011 Jul; 140(1):91-99. PubMed ID: 21106656
[TBL] [Abstract][Full Text] [Related]
2. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of midregional proatrial natriuretic peptide in patients with hemorrhagic stroke.
Fischer M; Katan M; Morgenthaler NG; Seiler M; Müller B; Lackner P; Errath M; Helbok R; Pfausler B; Beer R; Schmutzhard E; Broessner G
Cerebrovasc Dis; 2014; 37(2):128-33. PubMed ID: 24481415
[TBL] [Abstract][Full Text] [Related]
4. Plasma pro-adrenomedullin but not plasma pro-endothelin predicts survival in exacerbations of COPD.
Stolz D; Christ-Crain M; Morgenthaler NG; Miedinger D; Leuppi J; Müller C; Bingisser R; Struck J; Müller B; Tamm M
Chest; 2008 Aug; 134(2):263-272. PubMed ID: 18490402
[TBL] [Abstract][Full Text] [Related]
5. Plasma N-terminal B-Type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: comparison with plasma midregional pro-atrial natriuretic peptide: the LAMP (Leicester Acute Myocardial Infarction Peptide) study.
Khan SQ; Dhillon O; Kelly D; Squire IB; Struck J; Quinn P; Morgenthaler NG; Bergmann A; Davies JE; Ng LL
J Am Coll Cardiol; 2008 May; 51(19):1857-64. PubMed ID: 18466800
[TBL] [Abstract][Full Text] [Related]
6. Midregional pro-A-type natriuretic peptide and carboxy-terminal provasopressin may predict prognosis in community-acquired pneumonia.
Masiá M; Papassotiriou J; Morgenthaler NG; Hernández I; Shum C; Gutiérrez F
Clin Chem; 2007 Dec; 53(12):2193-201. PubMed ID: 17951293
[TBL] [Abstract][Full Text] [Related]
7. MR-pro-atrial natriuretic peptide (MR-proANP) predicts short- and long-term outcomes in respiratory tract infections: a prospective validation study.
Vazquez M; Jockers K; Christ-Crain M; Zimmerli W; Müller B; Schuetz P
Int J Cardiol; 2012 Apr; 156(1):16-23. PubMed ID: 21093937
[TBL] [Abstract][Full Text] [Related]
8. Circulating levels of pro-atrial natriuretic peptide in lower respiratory tract infections.
Müller B; Süess E; Schuetz P; Müller C; Bingisser R; Bergmann A; Stolz D; Tamm M; Morgenthaler NG; Christ-Crain M
J Intern Med; 2006 Dec; 260(6):568-76. PubMed ID: 17116008
[TBL] [Abstract][Full Text] [Related]
9. Midregional-proAtrial Natriuretic Peptide and High Sensitive Troponin T Strongly Predict Adverse Outcome in Patients Undergoing Percutaneous Repair of Mitral Valve Regurgitation.
Wöhrle J; Karakas M; Trepte U; Seeger J; Gonska B; Koenig W; Rottbauer W
PLoS One; 2015; 10(9):e0137464. PubMed ID: 26368980
[TBL] [Abstract][Full Text] [Related]
10. Increased plasma concentrations of midregional proatrial natriuretic Peptide is associated with risk of cardiorenal dysfunction in type 1 diabetes.
Theilade S; Hansen TW; Goetze JP; Rossing P
Am J Hypertens; 2015 Jun; 28(6):772-9. PubMed ID: 25468806
[TBL] [Abstract][Full Text] [Related]
11. MR-proANP improves prediction of mortality and cardiovascular events in patients with STEMI.
Lindberg S; Jensen JS; Pedersen SH; Galatius S; Goetze JP; Mogelvang R
Eur J Prev Cardiol; 2015 Jun; 22(6):693-700. PubMed ID: 24906365
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of midregional pro-atrial natriuretic peptide in ventilator-associated pneumonia.
Seligman R; Papassotiriou J; Morgenthaler NG; Meisner M; Teixeira PJ
Intensive Care Med; 2008 Nov; 34(11):2084-91. PubMed ID: 18523752
[TBL] [Abstract][Full Text] [Related]
13. Pro-atrial natriuretic peptide and pro-vasopressin for predicting short-term and long-term survival in community-acquired pneumonia: results from the German Competence Network CAPNETZ.
Krüger S; Ewig S; Kunde J; Hartmann O; Suttorp N; Welte T;
Thorax; 2010 Mar; 65(3):208-14. PubMed ID: 20335288
[TBL] [Abstract][Full Text] [Related]
14. Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death.
Moertl D; Berger R; Struck J; Gleiss A; Hammer A; Morgenthaler NG; Bergmann A; Huelsmann M; Pacher R
J Am Coll Cardiol; 2009 May; 53(19):1783-90. PubMed ID: 19422985
[TBL] [Abstract][Full Text] [Related]
15. Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes.
Zabarovskaja S; Hage C; Linde C; Daubert JC; Donal E; Gabrielsen A; Mellbin L; Lund LH
Int J Cardiol; 2015; 189():6-11. PubMed ID: 25885866
[TBL] [Abstract][Full Text] [Related]
16. Midregional pro-A-type natriuretic peptide for diagnosis and prognosis in patients with suspected acute myocardial infarction.
Meune C; Twerenbold R; Drexler B; Balmelli C; Wolf C; Haaf P; Reichlin T; Irfan A; Reiter M; Zellweger C; Meissner J; Stelzig C; Freese M; Capodarve I; Mueller C
Am J Cardiol; 2012 Apr; 109(8):1117-23. PubMed ID: 22257708
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ.
Krüger S; Ewig S; Giersdorf S; Hartmann O; Suttorp N; Welte T;
Am J Respir Crit Care Med; 2010 Dec; 182(11):1426-34. PubMed ID: 20639437
[TBL] [Abstract][Full Text] [Related]
18. The natriuretic peptide MR-proANP predicts all-cause mortality and adverse outcome in community patients: a 10-year follow-up study.
Odermatt J; Hersberger L; Bolliger R; Graedel L; Christ-Crain M; Briel M; Bucher HC; Mueller B; Schuetz P
Clin Chem Lab Med; 2017 Aug; 55(9):1407-1416. PubMed ID: 28107168
[TBL] [Abstract][Full Text] [Related]
19. Midregional pro-atrial natriuretic peptide and procalcitonin improve survival prediction in VAP.
Boeck L; Eggimann P; Smyrnios N; Pargger H; Thakkar N; Siegemund M; Marsch S; Rakic J; Tamm M; Stolz D
Eur Respir J; 2011 Mar; 37(3):595-603. PubMed ID: 20530040
[TBL] [Abstract][Full Text] [Related]
20. Midregional pro-atrial natriuretic peptide is a useful indicator for the detection of impaired left ventricular function in patients with coronary artery disease.
Elmas E; Brueckmann M; Lang S; Kälsch T; Haghi D; Sueselbeck T; Dempfle CE; Borggrefe M
Int J Cardiol; 2008 Aug; 128(2):244-9. PubMed ID: 17673312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
